As the world races to find a vaccine for COVID-19, there’s a glimmer of hope: Sanofi is investing $425 million (roughly P21.30 billion) to expand its vaccine development venture with US start-up Translate Bio for a vaccine.
The French pharma company is also working with GlaxoSmithKline Plc for another vaccine, which they expect to get approval by the first half of next year. If approved, it would be available in the second half of the year.
To date, the World Health Organization recorded 8.9 million cases and 469,159 deaths around the world. As of today, the Department of Health recorded close to 32,000 total active cases and close to 1,200 total deaths in the Philippines.
Just yesterday, Sanofi’s chief executive officer Paul Hudson said that they have “the only vaccine in the race which is offering a proven platform which works at scale.”
He added, “We are a little bit slower but we are much more likely to have success.”
Clinial trials for Sanofi’s vaccine with GSK are expected to start this September, while trials with Translate Bio will begin in the end of the year.
What do you think? Share your thoughts below!
Do you have a story for the WhenInManila.com Team? Email us at email@example.com or send us a direct message at WhenInManila.com Facebook Page. Interact with the team and join the WhenInManila.com Community at WIM Squad. Join our Viber group to be updated with the latest news!